Live Biotherapeutics Drug Discovery Service for Osteoporosis
Creative Biolabs is an innovative contract research services company. We rely on scientists, for scientists, as experts in the field of live biotherapeutics research. We offer a full range of products and services to support the research and development of next-generation probiotics.
Osteoporosis
Osteoporosis is characterized by increased osteoclast function followed by increased bone resorption and a corresponding decrease in bone formation. The most prevalent causes of osteoporosis are menopause and age.
-
Primary osteoporosis
-
Secondary osteoporosis
Secondary osteoporosis is caused by many medical and pathological factors, such as smoking, inflammatory bowel disease (IBD), type 1 diabetes (T1D), arthritis, hyperparathyroidism, and glucocorticoid treatment.
Role of Probiotics in Bone Health
The gut microbiota is an important regulator of physiological functions in many organs, including bone, and is also an increasingly interesting therapeutic target. To study the mediators of microbiota-dependent bone mass regulation will use Germ-free (GF) mouse models. The gut is known to play a key role in the absorption of calcium, phosphorus, and magnesium (which promotes bone mineralization), but it also produces endocrine factors. Thus, probiotics that alter flora composition and/or function and promote gut health may also benefit bone health. These mechanisms are not mutually exclusive but can work together to provide benefits to the host skeletal system and serve as a starting point for research. Given that probiotics are generally considered safe, future research to determine the mechanism is necessary. The mechanisms accounting for probiotic benefits on bone are likely to involve:
-
Modifying intestinal barrier function.
-
Changing the intestinal microbiome.
-
Impacting the immune system/immune cells.
Fig.1 Probiotic ingestion alters gastrointestinal function.
Gut Microbiome as a Target for Osteoporosis Treatment
Animal studies have provided evidence for the role of gut microbiota in regulating bone mass gain and bone remodeling. In animal models, probiotics prevent bone loss related to estrogen deficiency, diabetes, or glucocorticoid therapy by regulating bone absorption of osteoclasts and bone formation of osteoblasts. GM-targeted therapies provide a new therapeutic option for treating bone metabolic diseases like osteoporosis.
In humans, probiotics can interfere with the intake and absorption of calcium and 25-hydroxyvitamin D levels, slightly reducing bone loss in elderly postmenopausal women to a degree very similar to that observed with calcium and vitamin D supplementation.
Next-generation Probiotic Strains at Creative Biolabs
Creative Biolabs can offer a range of next-generation probiotics for live biotherapeutics research, including but not limited to the following, click on Probiotic Strains to check out more strains you might be interested in.
Our Services for the Following Type/Similar Osteoporosis Research
|
Research Article
|
Available Services
|
|
Lactobacillus rhamnosus GG ameliorates osteoporosis in ovariectomized rats.2
|
|
|
Anti-Osteoporotic effect of Lactobacillus brevis AR281 in an ovariectomized mouse model mediated with osteoclast differentiation inhibitio.3
|
|
Future research goals should focus on determining the mechanisms by which probiotics/microbiota improve osteoblast activity. These studies are of great significance for developing future treatment methods for osteoporosis. Creative Biolabs is a trusted supplier and partner in pharmaceutical and life science research with a global distribution network. We are proud to be a team of scientists, providing high-quality services to scientists in different areas of research and development. If you are interested in our service area, please feel free to contact us for more.
References
-
Guo, Mengyu, et al. "Lactobacillus rhamnosus GG ameliorates osteoporosis in ovariectomized rats by regulating the Th17/Treg balance and gut microbiota structure." Gut Microbes 15.1 (2023): 2190304.
-
Yu, Jing, et al. "Anti-osteoporotic effect of lactobacillus brevis AR281 in an ovariectomized mouse model mediated by inhibition of osteoclast differentiation." Biology 11.3 (2022): 359.
-
Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
